Skip to main content
Premium Trial:

Request an Annual Quote

Personalis Raises $33M in Series C Round: Plans to Scale up Operations

NEW YORK (GenomeWeb) – Personalis has raised $33 million in a Series C financing round, bringing the total amount of venture capital raised to date to $75 million.

Lightspeed Venture Partners was the lead investor in the new round. It was joined by all Series A investors, including Abingworth and Mohr Davidow Ventures.

Menlo Park, Calif.-based Personalis plans to use the new funding to scale up its operations. "With a broadening customer base and strong repeat orders, this additional capital will be important for driving our rapid and continued expansion," CEO John West said in a statement.

Last fall, Personalis launched cancer genome analysis services — the ACE Exome for Cancer and the ACE Extended Cancer Panel — and updated its existing ACE Clinical Exome test for inherited diseases.

"We have had a very positive response to our new offerings in cancer genomics, especially from pharmaceutical customers, and our Mendelian genetic testing business continues to grow," West said.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.